On this episode of the podcast, former Deputy Assistant Secretary of Health at the Department of Health & Human Resources David Mansdoerfer discusses President Donald Trump’s new executive order to reduce drug prices by up to 80% — requiring pharmaceutical companies to match the lowest prices of ‘most-favored-nations.’ Mansdoerfer highlights that this policy was anticipated and previously aligned with the president’s first term actions. He noted that while the pharmaceutical industry may initially resist, the order could benefit by preventing price gouging in foreign markets.

Furthermore, the conversation touches on the broader implications of the order, including potential backlash, the role of Medicare in drug pricing, and the impact of COVID-19 policies on public health.

You can keep up with David or Amanda on X by following their accounts: @Dpmansdo and @AmandaHead.